Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy

Cardiovascular Research

Volumn 44, Issue 1, 1999, Pages 20-36

  Redwood, Charles S ^a   Moolman Smook, Johanna C ^a,b   Watkins, Hugh ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Cardiomyopathy; Contractile proteins; Heart muscle; Hypertrophy; Mutation

Indexed keywords

CONTRACTILE PROTEIN; MUTANT PROTEIN; MYOSIN ADENOSINE TRIPHOSPHATASE; MYOSIN LIGHT CHAIN; TROPOMYOSIN; TROPONIN C; TROPONIN T;

DISEASE SEVERITY; HEART MUSCLE CONTRACTILITY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MISSENSE MUTATION; MOLECULAR GENETICS; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW;

EID: 0033214976     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00213-8     Document Type: Review

References (108)

1. Maron B.J., Gardin J.M., Flack J.M., et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 92:1995;785-789.
2. Watkins H., Seidman J.G., Seidman C.E. Familial hypertrophic cardiomyopathy: a genetic model of cardiac hypertrophy. Hum. Mol. Genet. 4:1995;1721-1727.
3. Maron B.J., Bonow R.O., Cannon R.O., Leon M.B., Epstein S.E. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2). New Engl. J. Med. 316:1987;844-852.
4. Maron B.J., Bonow R.O., Cannon R.O., Leon M.B., Epstein S.E. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). New Engl. J. Med. 316:1987;780-789.
5. Spirito P., Seidman C.E., McKenna W.J., Maron B.J. The management of hypertrophic cardiomyopathy. New Engl. J. Med. 336:1997;775-785.
6. Geisterfer-Lowrance A.A., Kass S., Tanigawa G., et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell. 62:1990;999-1006.
7. Watkins H., Rosenzweig A., Hwang D.S., et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy [see comments]. New Engl. J. Med. 326:1992;1108-1114.
8. Poetter K., Jiang H., Hassanzadeh S., et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat. Genet. 13:1996;63-69.
9. Watkins H., Conner D., Thierfelder L., et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat. Genet. 11:1995;434-437.
10. Bonne G., Carrier L., Bercovici J., et al. Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat. Genet. 11:(4):1995;438-440.
11. Thierfelder L., Watkins H., MacRae C., et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell. 77:1994;701-712.
12. Watkins H., McKenna W.J., Thierfelder L., et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. New Engl. J. Med. 332:1995;1058-1064.
13. Kimura A., Harada H., Park J.-E., et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat. Genet. 16:1997;379-382.
14. McKenna W.J., Watkins H. Hypertrophic cardiomyopathy. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The metabolic and molecular bases of inherited disease. 1995;McGraw Hill.
15. Epstein N.D., Cohn G.M., Cyran F., Fananapazir L. Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the beta-myosin heavy chain gene. A 908Leu-Val mutation and a 403Ar-Gln mutation [see comments]. Circulation. 86:1992;345-352.
16. Anan R., Greve G., Thierfelder L., et al. Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy [see comments]. J. Clin. Invest. 93:1994;280-285.
17. Fananapazir L., Epstein N.D. Genotype-phenotype correlations in hypertrophic cardiomyopathy. Insights provided by comparisons of kindreds with distinct and identical β myosin heavy chain gene mutations. Circulation. 89:1994;22-32.
18. Moolman J.C., Corfield V.A., Posen B., et al. Sudden death due to troponin T mutations. J. Am. Coll. Cardiol. 29:1997;549-555.
19. Niimura H., Bachinski L.L., Sangwatanaroj S., et al. Mutations in the gene for cardiac myosin-binding protein-C and late-onset familial hypertrophic cardiomyopathy. New Engl. J. Med. 338:1998;1248-1257.
20. Charron P., Dubourg O., Desnos M., et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation. 97:1998;2230-2236.
21. Flavigny J., Richard P., Isnard R., et al. Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy. J. Mol. Med. 76:1998;208-214.
22. Anan R., Shono H., Kisanuki A., Arima S., Nakao S., Tanaka H. Patients with familial hypertrophic cardiomyopathy caused by a Phe110Ile missense mutation in the cardiac troponin T gene have variable cardiac morphologies and a favorable prognosis. Circulation. 98:1998;391-397.
23. Herskowitz I. Functional inactivation of genes by dominant negative mutations. Nature. 329:1987;219-222.
24. Schwartz K. Familial hypertrophic cardiomyopathy. Nonsense versus missense mutations. Circulation. 91:1995;2865-2867.
25. Watkins H., Seidman C.E., Seidman J.G., Feng H.S., Sweeney H.L. Expression and functional assessment of a truncated cardiac troponin T that causes hypertrophic cardiomyopathy. Evidence for a dominant negative action [see comments]. J. Clin. Invest. 98:1996;2456-2461.
26. Bottinelli R., Coviello D.A., Redwood C.S., et al. A mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed in vivo and associated with an increased calcium sensitivity. Circ. Res. 82:1998;106-115.
27. Nishi H., Kimura A., Harada H., et al. A myosin missense mutation, not a null allele, causes familial hypertrophic cardiomyopathy [see comments]. Circulation. 91:1995;2911-2915.
28. Geisterfer-Lowrance A.A., Christe M., Conner D.A., et al. A mouse model of familial hypertrophic cardiomyopathy. Science. 272:1996;731-734.
29. Evans C.C., Wolska B.M., Muthuchamy M., Wieczorek D.F., Solaro R.J. Transgenic mouse hearts with a point mutation in a-tropomyosin show altered myofilament sensitivity to calcium, independent of phosphorylation state. Biophys. J. 74:(2):1998;A346.
30. Kretsinger R.H. Structure and evolution of calcium modulated proteins CRC. Crit. Rev. Biochem. 8:1980;119-174.
31. Trybus K.M. Role of myosin light chains. J. Muscle Res. Cell Motil. 15:1994;587-594.
32. Rayment I., Rypniewski W.R., Schmidt Base K., et al. Three-dimensional structure of myosin subfragment - 1: a molecular motor [see comments]. Science. 261:1993;50-58.
33. Warrick H.M., Spudich J.A. Myosin structure and function in cell motility. Annu. Rev. Cell Biol. 3:1987;379-421.
34. Goodson H.V., Spudich J.A. Molecular evolution of the myosin family: relationships derived from comparisons of amino acid sequences. Proc. Natl. Acad. Sci. USA. 90:1993;659-663.
35. Rayment I., Holden H.M., Sellers J.R., Fananapazir L., Epstein N.D. Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proc. Natl. Acad. Sci. USA. 92:1995;3864-3868.
36. Marian A.J., Yu Q.T., Mares A., Hill R., Roberts R., Perryman M.B. Detection of a new mutation in the β-myosin heavy chain gene in an individual with hypertrophic cardiomyopathy. J. Clin. Invest. 90:1992;2156-2165.
37. Gruen M., Gautel M. Mutations in beta-myosin S2 that cause familial hypertrophic cardiomyopathy (FHC) abolish the interaction with the regulatory domain of myosin-binding protein-C. J. Mol. Biol. 286:1999;933-949.
38. Kron S.J., Toyoshima Y.Y., Uyeda T.Q., Spudich J.A. Assays for actin sliding movement over myosin-coated surfaces. Methods Enzymol. 196:1991;399-416.
39. Homsher E., Wang F., Sellers J.R. Factors affecting movement of F-actin filaments propelled by skeletal muscle heavy meromyosin. Am. J. Physiol. 262:1992;C714-C723.
40. Cuda G., Fananapazir L., Zhu W.S., Sellers J.R., Epstein N.D. Skeletal muscle expression and abnormal function of beta-myosin in hypertrophic cardiomyopathy. J. Clin. Invest. 91:1993;2861-2865.
41. Straceski A.J., Geisterfer-Lowrance A., Seidman C.E., Seidman J.G., Leinwand L.A. Functional analysis of myosin missense mutations in familial hypertrophic cardiomyopathy. Proc. Natl. Acad. Sci. USA. 91:1994;589-593.
42. Marian A.J., Yu Q.T., Mann D.L., Graham F.L., Roberts R. Expression of a mutation causing hypertrophic cardiomyopathy disrupts sarcomere assembly in adult feline myocytes. Circ. Res. 77:1995;98-106.
43. Becker K.D., Gottshall K.R., Hickey R., Perriard J.-C., Chien K.R. Point mutations in human β cardiac myosin heavy chain have differential effects on sarcomeric structure and assembly: an ATP binding site change disrupts both thick and thin filaments, whereas hypertrophic cardiomyopathy mutations display normal assembly. J. Cell Biol. 137:1997;131-140.
44. Sweeney H.L., Straceski A.J., Leinwand L.A., Tikunov B.A., Faust L. Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. J. Biol. Chem. 269:1994;1603-1605.
45. Sata M., Ikebe M. Functional analysis of the mutations in the human cardiac β-myosin that are responsible for familial hypertrophic cardiomyopathy. J. Clin. Invest. 98:1996;2866-2873.
46. Fujita H., Sugiura S., Momomura S.-I., et al. Characterization of mutant myosins of Dictyostelium discoideum equivalent to human familial hypertrophic cardiomyopathy mutants. J. Clin. Invest. 99:1997;1010-1015.
47. Eldin P., Le Cunff M., Mornet D., Leger J.J. The cardiac myosin heavy chain arg-403→gln mutation that causes hypertrophic cardiomyopathy does not affect the actin- or ATP-binding capacities of two size-limited recombinant myosin heavy chain fragments. Biochem. J. 306:1995;345-351.
48. Lankford E.B., Epstein N.D., Fananapazir L., Sweeney H.L. Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J. Clin. Invest. 95:1995;1409-1414.
49. 1-cardiac myosin isolated from a mouse model of FHC moves actin slower and has altered unitary mechanics. Biophys. J. 74:1998;A121.
50. Tohtong R., Yamashita H., Graham M., et al. Impairment of muscle function caused by mutations of phosphorylation sites in myosin regulatory light chain. Nature. 374:1995;650-653.
51. Steiger G.J. Stretch activation and myogenic oscillation of isolated contractile structures of heart muscle. Pflugers. Arch. 330:1971;347-361.
52. Pringle J.W. The Croonian Lecture, 1977: Stretch activation of muscle:function and mechanism. Proc. R. Soc. London B. Biol. Sci. 201:1977;107-130.
53. Levine R.J.C., Yang Z., Epstein N.D., et al. Structural and functional responses to mammalian thick filaments to alterations in myosin regulatory light chains. J. Structural Biol. 122:1998;149-161.
54. Freiburg A., Gautel M. A molecular map of the interactions between titin and myosin-binding protein C. Implications for sarcomeric assembly in familial hypertrophic cardiomyopathy. Eur. J. Biochem. 235:1996;317-323.
55. Okagaki T., Weber F.E., Fischman D.A., et al. The major myosin-binding domain of skeletal muscle MyBP-C (C protein) resides in the COOH-terminal, immunoglobulin C2 motif. J. Cell Biol. 123:1993;619-626.
56. Musacchio A., Wilmanns M., Saraste M. Structure and function of the SH3 domain. Prog. Biophys. Mol. Biol. 61:1994;283-297.
57. 2+-calmodulin-dependent protein kinases. J. Biol. Chem. 259:1984;15587-15596.
58. Schlender K.K., Bean L.J. Phosphorylation of chicken cardiac C-protein by calcium/calmodulin-dependent protein kinase II. J. Biol. Chem. 266:1991;2811-2817.
59. Gautel M., Zuffardi O., Freiburg A., Labeit S. Phosphorylation switches specific for the cardiac isoform of myosin binding protein-C: a modulator of cardiac contraction? EMBO J. 14:1995;1952-1960.
60. r 150 000 in perfused rat heart, and the tentative identification of this as C-protein. FEBS Lett. 122:1980;129-132.
61. Garvey J.L., Kranias E.G., Solaro R.J. Phosphorylation of C-protein, troponin I and phospholamban in isolated rabbit hearts. Biochem. J. 249:1988;709-714.
62. Hartzell H.C., Titus L. Effects of cholinergic and adrenergic agonists on phosphorylation of a 165 000 Da myofibrillar protein in intact cardiac muscle. J. Biol. Chem. 257:1982;2111-2120.
63. Moos C., Mason C.M., Besterman J.M., Feng I.N., Dubin J.H. The binding of skeletal muscle C-protein to F-actin, and its relation to the interaction of actin with myosin subfragment-1. J. Mol. Biol. 124:1978;571-586.
64. Carrier L., Bonne G., Bahrend E., et al. Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. Circ. Res. 80:1997;427-434.
65. Yu B., French J.A., Carrier L., et al. Molecular pathology of familial hypertrophic cardiomyopathy caused by mutations in the cardiac myosin binding protein C gene. J. Med. Genet. 35:1998;205-210.
66. Moolman-Smook J.C., Mayosi B., Brink P., Corfield V.A. Identification of a new missense mutation in MyBP-C associated with hypertrophic cardiomyopathy. J. Med. Genet. 35:1998;253-254.
67. Gilbert R., Kelly M.G., Mikawa T., Fischman D.A. The carboxyl terminus of myosin binding protein C (MyBP-C, C-protein) specifies incorporation into the A-band of striated muscle. J. Cell Sci. 109:1996;101-111.
68. Rottbauer W., Gautel M., Zehelein J., et al. Novel splice donor mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy. J. Clin. Invest. 100:1997;475-482.
69. Moolman J., Uhl K., Jeschke B., Gautel M., Vosberg H.-P. A newly created splice donor site in the MyBP-C gene causes hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol. abstract book. 30:():1998;A30.
70. Yang Q., Sanbe A., Osinska H., et al. A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. J. Clin. Invest. 102:1998;1292-1300.
71. Grabarek Z., Drabikowski W., Leavis P.C., Rosenfeld S.S., Gergely J. Proteolytic fragments of troponin C. Interactions with the other troponin subunits and biological activity. J. Biol. Chem. 256:1981;13121-13127.
72. Zot A.S., Potter J.D. Structural aspects of troponin-tropomyosin regulation of skeletal muscle contraction. Annu. Rev. Biophys. Biophys. Chem. 16:1987;535-559.
73. Farah C.S., Reinach F.C. The troponin complex and regulation of muscle contraction. FASEB J. 9:1995;755-767.
74. Forissier J.F., Carrier L., Farza H., et al. Codon 102 of the cardiac troponin T gene is a putative hot spot for mutations in familial hypertrophic cardiomyopathy. Circulation. 94:1996;3069-3073.
75. Lin D., Bobkova A., Homsher E., Tobacman L.S. Altered cardiac troponin T in vitro function in the presence of a mutation implicated in familial hypertrophic cardiomyopathy. J. Clin. Invest. 97:1996;2842-2848.
76. Lee D.M., Tobacman L.S., Homsher E. Calcium dependence of isometric force measured in single thin filaments using glass microneedles. Biophys. J. 74:1998;A347.
77. Butters C., Landis C., Lin D., Homsher E., Tobacman L. Properties of troponin with TnT mutations corresponding to those found in hypertrophic cardiomyopathy. Biophys. J. 74:1998;A52.
78. Mukherjea P., Seidman J.G., Seidman C.E., Watkins H., Hitchcock-DeGregori S.E. Altered regulatory function of two FHC troponin T mutants. Biophys. J. 74:1998;A51.
79. Sweeney H.L., Feng H.S., Yang Z., Watkins H. Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function. Proc. Natl. Acad. Sci. USA. 95:1998;14406-14410.
80. 2+-sensitizing effects of the mutations at Ile-79 and Arg-92 of troponin T in hypertrophic cardiomyopathy. Am. J. Physiol. 275:1998;C200-C207.
81. Hatakenaka M., Ohtsuki I. Replacement of three troponin components with cardiac troponin components within single glycerinated skeletal muscle fibers. Biochem. Biophys. Res. Commun. 181:1991;1022-1027.
82. 2+-activated tension development of single glycerinated skeletal muscle fibers. Eur. J. Biochem. 205:1992;985-993.
83. Marian A.J., Zhao G., Seta Y., Roberts R., Yu Q.T. Expression of a mutant (Arg92Gln) human cardiac troponin T., known to cause hypertrophic cardiomyopathy, impairs adult cardiac myocyte contractility. Circ. Res. 81:1997;76-85.
84. el Saleh S.C., Warber K.D., Potter J.D. The role of tropomyosin-troponin in the regulation of skeletal muscle contraction. J. Muscle Res. Cell Motil. 7:1986;387-404.
85. Phillips G.N. Jr., Fillers J.P., Cohen C. Tropomyosin crystal structure and muscle regulation. J. Mol. Biol. 192:1986;111-131.
86. Ishii Y., Lehrer S.S. Fluorescence probe studies of the state of tropomyosin in reconstituted muscle thin filaments. Biochemistry. 26:1987;4922-4925.
87. Monteiro P.B., Lataro R.C., Ferro J.A., Reinach F. Functional alpha-tropomyosin produced in Escherichia coli. A dipeptide extension can substitute the amino-terminal acetyl group. J. Biol. Chem. 269:1994;10461-10466.
88. 2+ regulation of thin filament motility. Biochem. Biophys. Res. Commun. 236:1997;760-764.
89. 2+ regulation of thin filaments. Biophys. J. 74:(2):1998;A354.
90. Golitsina N., An Y., Greenfield N.J., et al. Effects of two familial hypertrophic cardiomyopathy-causing mutations on alpha-tropomyosin structure and function. Biochemistry. 36:1997;4637-4642.
91. Syska H., Wilkinson J.M., Grand R.J., Perry S.V. The relationship between biological activity and primary structure of troponin I from white skeletal muscle of the rabbit. Biochem. J. 153:1976;375-387.
92. Talbot J.A., Hodges R.S. Synthetic studies on the inhibitory region of rabbit skeletal troponin I. J. Biol. Chem. 256:1981;2798-2802.
93. Van Eyk J.E., Hodges R.S. The biological importance of each amino acid residue of the troponin I inhibitory sequence 104-115 in the interaction with troponin C and tropomyosin-actin. J. Biol. Chem. 263:1988;1726-1732.
94. 2+ sensitivity of the acto-S1-TM ATPase. J. Biol. Chem. 272:1997;10529-10537.
95. Tripet B., Van Eyk J.E., Hodges R.S. Mapping of a second troponin C binding site within the C terminus of troponin I., and their importance in the Ca2+-dependent regulation of muscle contraction. J. Mol. Biol. 271:1997;728-750.
96. 2+ sensitivity of rat myofibrils. J. Biol. Chem. 272:1997;26887-26892.
97. 2- and COOH-terminal regions of skeletal muscle troponin I. J. Biol. Chem. 269:1994;5230-5240.
98. 2+.troponin C.troponin I derived from small-angle scattering data: implications for regulation. Biochemistry. 33:1994;12800-12806.
99. Redwood C.S., Elliott K., Watkins H.C. Defective inhibitory properties of human cardiac troponin I mutants that cause familial hypertrophic cardiomyopathy (FHC). Circulation. 98:1998;I-466.
100. Roopnarine O., Leinwand L.A. Functional analysis of myosin mutations that cause familial hypertrophic cardiomyopathy. Biophys. J. 75:1999;3023-3030.
101. Marian A.J., Mares A., Kelly D.P., et al. Sudden cardiac death in hypertrophic cardiomyopathy. Variability in phenotypic expression of β-myosin heavy chain mutations. Eur. Heart J. 16:1995;368-376.
102. 403/+ mouse model of familial hypertrophic cardiomyopathy. J. Clin. Invest. 101:1998;1775-1783.
103. Watkins H., Thierfelder L., Hwang D.S., et al. Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations. J. Clin. Invest. 90:1992;1666-1671.
104. Fananapazir L., Dalakas M.C., Cyran F., Cohn G., Epstein N.D. Missense mutations in the beta-myosin heavy-chain gene cause central core disease in hypertrophic cardiomyopathy. Proc. Natl. Acad. Sci. USA. 90:1993;3993-3997.
105. Greve G., Bachinski L., Friedman D.L., et al. Isolation of a de novo mutant myocardial beta MHC protein in a pedigree with hypertrophic cardiomyopathy. Hum. Mol. Genet. 3:1994;2073-2075.
106. Consevage M.W., Salada G.C., Baylen B.G., Ladda R.L., Rogan P.K. A new missense mutation, Arg719Gln, in the beta-cardiac heavy chain myosin gene of patients with familial hypertrophic cardiomyopathy. Hum. Mol. Genet. 3:1994;1025-1026.
107. Nakajima-Taniguchi C., Matsui H., Nagata S., Kishimoto T., Yamauchi-Takihara K. Novel missense mutation in α-tropomyosin gene found in Japanese patients with hypertrophic cardiomyopathy. J. Mol. Cell Cardiol. 27:1995;2053-2058.
108. Nakajima-Taniguchi C., Matsui H., Nagata S., Kishimoto T., Yamauchi-Takihara K. Novel missense mutation in alpha-tropomyosin gene found in Japanese patients with hypertrophic cardiomyopathy. Heart. 76:1996;63-65.